The DNMT3A Knockout TE1 Polyclonal Cells are a human esophageal squamous cell carcinoma-derived polyclonal knockout cell population generated by CRISPR/Cas9-mediated disruption of the DNMT3A gene. These polyclonal knockout cells provide a heterogeneous loss-of-function model for studying epigenetic regulation in cancer, without selection for a single clonal genotype. The polyclonal format preserves population-level diversity, enabling robust functional studies including pooled screening and bulk assays.
The host cell line, TE1, is a well-characterized human esophageal squamous cell carcinoma cell line established from a primary tumor. TE1 cells retain features of esophageal squamous cell carcinoma, including genetic and epigenetic aberrations typical of this malignancy. This cellular background offers a clinically relevant platform for investigating the molecular mechanisms underlying esophageal squamous cell carcinoma progression and therapeutic responses.
DNMT3A encodes a DNA methyltransferase that catalyzes de novo DNA methylation by transferring methyl groups to CpG dinucleotides, thereby establishing methylation patterns critical for transcriptional silencing and epigenetic regulation. DNMT3A operates within a network of interacting epigenetic modifiers, forming complexes with DNMT3L, UHRF1, HDAC1, HDAC2, PCNA, and EZH2. Its expression is regulated by upstream factors including MYC, E2F transcription factors, STAT3, and TGF-beta signaling. Downstream, DNMT3A-mediated methylation modulates genes such as CDKN2A, MLH1, APC, and BRCA1, contributing to the control of cell cycle, DNA repair, and tumor suppression.
In esophageal squamous cell carcinoma, DNMT3A is implicated in aberrant DNA methylation patterns that promote malignant phenotypes. Disruption of DNMT3A in TE1 cells is expected to alter the epigenetic landscape, potentially reactivating silenced tumor suppressor genes and impairing proliferative capacity. This knockout model serves as a valuable tool to dissect DNMT3A-dependent mechanisms in esophageal squamous cell carcinoma, allowing researchers to examine changes in DNA methylation, gene expression, and chromatin organization in a disease-relevant context.
These polyclonal knockout cells are suitable for a broad range of applications, including Western blotting and RT-qPCR to confirm DNMT3A disruption, global DNA methylation analysis by ELISA or bisulfite sequencing, transcriptomic profiling via RNA-seq, chromatin immunoprecipitation sequencing (ChIP-seq) for histone modifications, and functional assays such as proliferation and apoptosis measurements. The model also supports drug sensitivity studies with hypomethylating agents like decitabine, facilitating the evaluation of epigenetic therapies. For further information on product performance and custom applications, please contact Ascent Research.
